Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Primmune is based at JLABS San Diego.
Primmune Therapeutics, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.primmunerx.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
AddressJLABS San Diego3210 Merryfield Row, CA, 92121San DiegoUnited States
JLABS San Diego3210 Merryfield Row, CA, 92121
San Diego
United States
Contact Number+1 888 505 7765
+1 888 505 7765
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/primmune-therapeutics” connections=”true” suffix=””]
The TLR7 receptor is expressed on plasmacytoid dendritic cells (pDCs) and B-cells and activation of pDCs produces cytokines and chemokines that up-regulate general cellular responses including NK (natural killer) cell activation, CTL (cytotoxic T-cell or CD8+ T-cell) activation and increase in proliferation and activation of B-cells.